EspeRare Secures Gates Foundation Grant for Preeclampsia Therapy

On December 3, 2025, Geneva-based nonprofit biotech EspeRare announced the receipt of a Grand Challenges grant from the Gates Foundation. This funding will advance their groundbreaking therapy for preeclampsia, a serious pregnancy complication. Characterized by high blood pressure and organ dysfunction, preeclampsia affects millions worldwide and remains a leading cause of maternal and neonatal mortality, particularly in low-resource areas.

The grant will enable EspeRare to further develop a therapy that repurposes an oral small molecule initially created for cardiovascular disorders. With an established safety profile, the project aims to accelerate clinical trials in pregnant women, seeking to produce a safe, effective, and accessible treatment. This initiative focuses on improving mother and child health outcomes, especially in high-burden regions.

This support from the Gates Foundation highlights the global focus on maternal and prenatal health. EspeRare is poised to expand its impact, continuing to innovate treatments for neglected maternal-fetal conditions and strengthening partnerships to bring science-based solutions to real-world healthcare challenges.